US EditionTrump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
The agreement with Eli Lilly and Novo Nordisk will reduce obesity drug costs to as low as $150 monthly for Medicare and Medicaid patients, expanding access for millions.
- President Trump announced deals with Eli Lilly and Novo Nordisk to cut prices of obesity drugs for Medicare and Medicaid beneficiaries in 2026.
- The deals will offer obesity treatments directly to consumers at discounted prices on a website called TrumpRx.gov starting in January.
- Certain Medicare patients will pay $50 per month for approved GLP-1 drugs, and upcoming obesity pills from Lilly and Novo Nordisk will cost $145 per month initially.
349 Articles
349 Articles
U.S. President Donald Trump announced Thursday agreements with pharmaceutical giants Eli Lilly and Novo Nordisk to reduce the prices of the most popular weight loss drugs, in exchange for tariff benefits and other benefits. Both companies “have agreed to offer their most popular GLP-1 weight loss medication with drastic discounts,” Trump told reporters at the White House. “It’s a triumph for American patients that will save lives and improve the…
The impact of lowering the cost of weight loss drugs
Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University.
U.S. deal could cut costs for popular weight-loss drugs. What’s that mean for Canada?
A new deal with major drugmakers, unveiled by U.S. President Donald Trump on Thursday, aims to expand coverage and cut prices for popular weight-loss drugs south of the border. So how much could Trump’s announcement really cut costs? And will Canadians also benefit?
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
